Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates

  • Immunic Inc IMUX has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday.
  • The gross proceeds are expected to be approximately $45 million.
  • Underwriters have an option to purchase up to an additional 675,000 shares.
  • The offering will close by July 19.
  • Piper Sandler is acting as the sole book-runner for the offering. Ladenburg Thalmann & Co. Inc., Roth Capital Partners, and Aegis Capital Corp. are acting as co-managers for the offering.
  • The Company will use the proceeds to fund the ongoing clinical development of its three lead product candidates, IMU-838, IMU-935, and IMU-856, and for other general corporate purposes.
  • Recently, the FDA signed off two trial applications for IMU-838 in multiple sclerosis.
  • Price Action: IMUX shares are down 18.1% at $9.70 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!